Table 96.6Intravenous Single-Agent and Combination Chemotherapy for HCC

DrugDose (mg/m2)No. of Pts. EvaluatedResponse (%)Median Survival (mo)Study
Doxorubicin60–75, q 3 wk475163–4Nerenstone and Freedman151
Cisplatin75 q 3 wk3563–53–5Falkson et al.165,166
Paclitaxel175 dL, q 3 wk2003Chao et al.167
Fluorouracil375 dL–5, q 5 wk55112.0Falkson et al.165,166
+ semustine150 dL, q 10 wk
Fluorouracil325 dL–5, q 5 wk
+ semustine110 dL, q 10 wk38213.0Falkson et al.165,166
+ doxorubicin40 dL, q 5 wk
Fluorouracil450 dL-5, C IV
+ cisplatin80 dL q 4 wk27336Okada et al168
+ mitoxantrone6 dL q 4 wk27336Okada et al168

From: Chapter 96, Primary Neoplasms of the Liver

Cover of Holland-Frei Cancer Medicine
Holland-Frei Cancer Medicine. 5th edition.
Bast RC Jr, Kufe DW, Pollock RE, et al., editors.
Hamilton (ON): BC Decker; 2000.
© 2000, BC Decker Inc.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.